Amina Jindani

St George's, University of London — United Kingdom

Medicine · Health Sciences

19h-index2.5kcitations42works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(26), Mycobacterium research and diagnosis(12), Pneumocystis jirovecii pneumonia detection and treatment(8), Diagnosis and treatment of tuberculosis(6), Pneumonia and Respiratory Infections(5)

Publications42 total

Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Clinical Infectious Diseases·2025Open Access
Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
Journal of Antimicrobial Chemotherapy·2025
Xpert MTB/RIF <sup>®</sup> cycle threshold as a marker of TB disease severity; Implications for TB treatment stratification
2025Open Access
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Nature Communications·2025Open Access
Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis
NEJM Evidence·2023· 29 citedOpen Access
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection
American Journal of Respiratory and Critical Care Medicine·2020· 34 citedOpen Access
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
The Lancet Respiratory Medicine·2019· 116 cited
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
Antimicrobial Agents and Chemotherapy·2019· 27 citedOpen Access
INTERTB Symposium 2018
St. George's University of London·2019Open Access
Denis Anthony Mitchison
BMJ·2018
INTERTB Symposium 2017
St. George's University of London·2018Open Access
Predictors of delayed culture conversion among Ugandan patients
BMC Infectious Diseases·2017· 8 citedOpen Access
Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial
BMC Medicine·2017· 58 citedOpen Access
Additional file 1: Table S1. of Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial
Figshare·2017Open Access
Additional file 1: of Predictors of delayed culture conversion among Ugandan patients
Figshare·2017Open Access
A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis
The International Journal of Tuberculosis and Lung Disease·2016· 54 cited
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
New England Journal of Medicine·2014· 436 citedOpen Access
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis
The International Journal of Tuberculosis and Lung Disease·2014· 10 cited
Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients
Antimicrobial Agents and Chemotherapy·2013· 44 citedOpen Access
Contradictory Results with High-Dosage Rifamycin in Mice and Humans
Antimicrobial Agents and Chemotherapy·2013· 11 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Thomas S. Harrison(10), Helen McIlleron(7), Andrew Nunn(6), Philip D. Butcher(6), Maryline Bonnet(5), Mark Hatherill(4), Simbarashe Zvada(4), D.A. Mitchison(4), Kelly E. Dooley(4), Adam A. Witney(4), Daniel Atwine(4), Patrick Phillips(3), Salome Charalambous(3), Stanley Mungofa(3), D. A. Enarson(3), M. Burgos(3), Paolo Denti(3), Lubbe Wiesner(3), Susan E. Dorman(3), Daniel Grint(3)